View Item 

Show simple item record

Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy
dc.contributor.authorHammer, Yoav
dc.contributor.authorBitar, Abbas
dc.contributor.authorAaronson, Keith D.
dc.date.accessioned2023-08-01T18:28:44Z
dc.date.available2024-09-01 14:28:44en
dc.date.available2023-08-01T18:28:44Z
dc.date.issued2023-08
dc.identifier.citationHammer, Yoav; Bitar, Abbas; Aaronson, Keith D. (2023). "Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy." ESC Heart Failure 10(4): 2214-2224.
dc.identifier.issn2055-5822
dc.identifier.issn2055-5822
dc.identifier.urihttps://hdl.handle.net/2027.42/177406
dc.description.abstractWhile technological advances in the field of continuous-flow left ventricular assist device (CF-LVAD) are constantly being made, CF-LVAD recipients are still subjected to a relatively high rate of LVAD-related adverse events, with post-LVAD gastrointestinal bleeding (GIB) being the most common one. GIB is associated with a significant impairment in quality of life, multiple hospital admissions, blood transfusion requirements and possibly death. Furthermore, of those patients who bled once, many will experience recurrent GIB events, which further aggravates their discomfort. While some medical and endoscopic treatment options are available, evidence regarding their benefit remains largely equivocal, with all related studies based on data from registries rather than clinical trials. Although having a major impact on LVAD recipients, an effective and validated pre-implant screening options to predict GIB events post-implant are scarce. This review focuses on the aetiology, incidence, risk factors, treatment options and the effect of new generation devices on post-LVAD GIB.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherGastrointestinal bleeding
dc.subject.otherArteriovenous malformations
dc.subject.otherContinuous-flow left ventricular assist device
dc.subject.otherHeartmate 3
dc.titleGastrointestinal bleeding on continuous-flow left ventricular assist device therapy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/177406/1/ehf214433_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/177406/2/ehf214433.pdf
dc.identifier.doi10.1002/ehf2.14433
dc.identifier.sourceESC Heart Failure
dc.identifier.citedreferenceJuricek C, Imamura T, Nguyen A, Chung B, Rodgers D, Sarswat N, Kim G, Raikhelkar J, Ota T, Song T, Burkhoff D, Sayer G, Jeevanandam V, Uriel N. Long-acting octreotide reduces the recurrence of gastrointestinal bleeding in patients with a continuous-flow left ventricular assist device. J Card Fail. 2018; 24: 249 – 254.
dc.identifier.citedreferenceJohansson C, Aly A. Stimulation of gastric mucus output by somatostatin in man. Eur J Clin Invest. 1982; 12: 37 – 39.
dc.identifier.citedreferenceShah KB, Gunda S, Emani S, Kanwar MK, Uriel N, Colombo PC, Uber PA, Sears ML, Chuang J, Farrar DJ, Brophy DF, Smallfield GB. Multicenter evaluation of octreotide as secondary prophylaxis in patients with left ventricular assist devices and gastrointestinal bleeding. Circ Heart Fail. 2017; 10.
dc.identifier.citedreferenceWilson TJ, Baran DA, Herre JM, Cameron CM, Yehya A, Ingemi AI. Gastrointestinal bleeding rates in left ventricular assist device population reduced with octreotide utilization. ASAIO J. 2021; 67: 989 – 994.
dc.identifier.citedreferenceDraper K, Kale P, Martin B, Kelly Cordero R, Ha R, Banerjee D. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant. 2015; 34: 132 – 134.
dc.identifier.citedreferenceSieg AC, Moretz JD, Horn E, Jennings DL. Pharmacotherapeutic management of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Pharmacotherapy. 2017; 37: 1432 – 1448.
dc.identifier.citedreferenceSeng BJJ, Teo LLY, Chan LL, Sim DKL, Kerk KL, Soon JL, Tan TE, Sivathasan C, Lim CP. Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients. Int J Artif Organs. 2017; 40: 636 – 640.
dc.identifier.citedreferenceNamdaran P, Zikos TA, Pan JY, Banerjee D. Thalidomide use reduces risk of refractory gastrointestinal bleeding in patients with continuous flow left ventricular assist devices. ASAIO J. 2020; 66: 645 – 651.
dc.identifier.citedreferenceBarkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol. 1998; 93: 1250 – 1254.
dc.identifier.citedreferencevan Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet. 1990; 335: 953 – 955.
dc.identifier.citedreferenceJunquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM, Saperas E, Piqué JM, Malagelada JR. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001; 121: 1073 – 1079.
dc.identifier.citedreferenceGutsche JT, Atluri P, Augoustides JG. Treatment of ventricular assist-device-associated gastrointestinal bleeding with hormonal therapy. J Cardiothorac Vasc Anesth. 2013; 27: 939 – 943.
dc.identifier.citedreferenceBeaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007; 2007: CD001017.
dc.identifier.citedreferenceSchettle SD, Pruthi RK, Pereira NL. Continuous-flow left ventricular assist devices and gastrointestinal bleeding: potential role of danazol. J Heart Lung Transplant. 2014; 33: 549 – 550.
dc.identifier.citedreferenceMathur P, Marino D, Bittner K, Bartell N, Taylor C, Aranez JL, Alexis J, Carlson B, Chen L, Ott L, Kothari TH, Kaul V, Kothari S. Su1395 initiation of danazol in left ventricular assist device patients with recurrent Gi bleeding leads to shorter hospital stays and fewer blood transfusions. Gastrointest Endosc. 2019; 89: AB361 – AB362.
dc.identifier.citedreferenceBartoli CR, Kang J, Restle DJ, Zhang DM, Shabahang C, Acker MA, Atluri P. Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiological shear stress: therapeutic implications for left ventricular assist device-associated bleeding. JACC Heart Fail. 2015; 3: 860 – 869.
dc.identifier.citedreferenceBartoli CR, Zhang DM, Hennessy-Strahs S, Kang J, Restle DJ, Bermudez C, Atluri P, Acker MA. Clinical and in vitro evidence that left ventricular assist device-induced von Willebrand factor degradation alters angiogenesis. Circ Heart Fail. 2018; 11: e004638.
dc.identifier.citedreferenceJames PD, Connell NT, Ameer B, di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R. Montgomery R, O’Donnell JS, Scappe N, Sidonio R Jr, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5: 280 – 300.
dc.identifier.citedreferenceHollis IB, Chen SL, Chang PP, Katz JN. Inhaled desmopressin for refractory gastrointestinal bleeding in a patient with a HeartMate II left ventricular assist device. ASAIO J. 2017; 63: e47 – e49.
dc.identifier.citedreferenceAsleh R, Albitar HAH, Schettle SD, Kushwaha SS, Pereira NL, Behfar A, Stulak JM, Rodeheffer RJ, Iyer VN. Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding. J Heart Lung Transplant. 2020; 39: 492 – 495.
dc.identifier.citedreferenceMehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C, MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017; 376: 440 – 450.
dc.identifier.citedreferenceHeatley G, Sood P, Goldstein D, Uriel N, Cleveland J, Middlebrook D, Mehra MR, MOMENTUM 3 Investigators. Clinical trial design and rationale of the multicenter study of MagLev technology in patients undergoing mechanical circulatory support therapy with HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant. 2016; 35: 528 – 536.
dc.identifier.citedreferenceKormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, Grady KL, Kirklin JK. The Society of Thoracic Surgeons Intermacs Database Annual Report: evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant. 2019; 38: 114 – 126.
dc.identifier.citedreferenceYuzefpolskaya M, Schroeder SE, Houston BA, Robinson MR, Gosev I, Reyentovich A, Koehl D, Cantor R, Jorde UP, Kirklin JK, Pagani FD, D’Alessandro DA. The Society of Thoracic Surgeons Intermacs 2022 Annual Report: focus on the 2018 Heart Transplant Allocation System. Ann Thorac Surg. 2023; 115: 311 – 327.
dc.identifier.citedreferenceMehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Itoh A, Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh F, Aaronson K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ, MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device - final report. N Engl J Med. 2019; 380: 1618 – 1627.
dc.identifier.citedreferenceMehra MR, Crandall DL, Gustafsson F, Jorde UP, Katz JN, Netuka I, Uriel N, Connors JM, Sood P, Heatley G, Pagani FD. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. Eur J Heart Fail. 2021; 23: 1226 – 1237.
dc.identifier.citedreferenceKataria R, Jorde UP. Gastrointestinal bleeding during continuous-flow left ventricular assist device support: state of the field. Cardiol Rev. 2019; 27: 8 – 13.
dc.identifier.citedreferenceDraper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014; 80: 435 – 446.e1.
dc.identifier.citedreferenceAggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, Pappas PS, Bhat G. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012; 93: 1534 – 1540.
dc.identifier.citedreferenceStern B, Maheshwari P, Gorrepati VS, Bethards D, Chintanaboina J, Boehmer J, Clarke K. Initial endoscopic intervention is not associated with reduced risk of recurrent gastrointestinal bleeding in left ventricular assist device patients. Ann Gastroenterol. 2021; 34: 660 – 668.
dc.identifier.citedreferencePatel SR, Oh KT, Ogriki T, Sims D, Shin JJ, Madan S, Saeed O, Goldstein DJ, Jorde UP. Cessation of continuous flow left ventricular assist device-related gastrointestinal bleeding after heart transplantation. ASAIO J. 2018; 64: 191 – 195.
dc.identifier.citedreferenceThohan V, Shi Y, Rappelt M, Yousefzai R, Sulemanjee NZ, Hastings TE, Cheema OM, Downey F, Crouch JD. The association between novel clinical factors and gastrointestinal bleeding among patients supported with continuous-flow left ventricular assist device therapy. J Card Surg. 2019; 34: 453 – 462.
dc.identifier.citedreferenceMarsano J, Desai J, Chang S, Chau M, Pochapin M, Gurvits GE. Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series. Dig Dis Sci. 2015; 60: 1859 – 1867.
dc.identifier.citedreferenceGurvits GE, Fradkov E. Bleeding with the artificial heart: gastrointestinal hemorrhage in CF-LVAD patients. World J Gastroenterol. 2017; 23: 3945 – 3953.
dc.identifier.citedreferenceWever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, Labedi M, Reid BB, Davis ES, Kfoury AG, Li DY, Stehlik J, Bader F. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013; 6: 517 – 526.
dc.identifier.citedreferenceMarasco SF, Summerhayes R, Quayle M, McGiffin D, Luthe M. Cost comparison of heart transplant vs. left ventricular assist device therapy at one year. Clin Transplant. 2016; 30: 598 – 605.
dc.identifier.citedreferenceStulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ, Aaronson KD, Pagani FD. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant. 2014; 33: 60 – 64.
dc.identifier.citedreferenceHernandez RE, Singh SK, Hoang DT, Ali SW, Elayda MAA, Mallidi HR, Frazier OH, Meyers DE. Present-day hospital readmissions after left ventricular assist device implantation: a large single-center study. Tex Heart Inst J. 2015; 42: 419 – 429.
dc.identifier.citedreferenceMolina TL, Krisl JC, Donahue KR, Varnado S. Gastrointestinal bleeding in left ventricular assist device: octreotide and other treatment modalities. ASAIO J. 2018; 64: 433 – 439.
dc.identifier.citedreferenceYin MY, Ruckel S, Kfoury AG, McKellar SH, Taleb I, Gilbert EM, Nativi-Nicolau J, Stehlik J, Reid BB, Koliopoulou A, Stoddard GJ, Fang JC, Drakos SG, Selzman CH, Wever-Pinzon O. Novel model to predict gastrointestinal bleeding during left ventricular assist device support. Circ Heart Fail. 2018; 11: e005267.
dc.identifier.citedreferenceLi F, Hinton A, Chen A, Mehta NK, Eldika S, Zhang C, Hussan H, Conwell DL, Krishna SG. Left ventricular assist devices impact hospital resource utilization without affecting patient mortality in gastrointestinal bleeding. Dig Dis Sci. 2017; 62: 150 – 160.
dc.identifier.citedreferenceCushing K, Kushnir V. Gastrointestinal bleeding following LVAD placement from top to bottom. Dig Dis Sci. 2016; 61: 1440 – 1447.
dc.identifier.citedreferenceBoyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD, HeartMate II Clinical Investigators. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014; 63: 880 – 888.
dc.identifier.citedreferenceGeisen U, Heilmann C, Beyersdorf F, Benk C, Berchtold-Herz M, Schlensak C, Budde U, Zieger B. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008; 33: 679 – 684.
dc.identifier.citedreferenceUriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A, Ennezat PV, Cappleman S, Naka Y, Mancini D. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010; 56: 1207 – 1213.
dc.identifier.citedreferenceDemirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, Bogaev RC, Frazier OH. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011; 30: 849 – 853.
dc.identifier.citedreferenceHuda SA, Kahlown S, Jilani MH, Chaudhuri D. Management of life-threatening bleeding in patients with mechanical heart valves. Cureus. 2021; 13: e15619.
dc.identifier.citedreferencePate GE, Chandavimol M, Naiman SC, Webb JG. Heyde’s syndrome: a review. J Heart Valve Dis. 2004; 13: 701 – 712.
dc.identifier.citedreferenceWarkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992; 340: 35 – 37.
dc.identifier.citedreferenceSuarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011; 4: 779 – 784.
dc.identifier.citedreferencePatel SR, Vukelic S, Chinnadurai T, Madan S, Sibinga N, Kwah J, Saeed O, Goldstein DJ, Jorde UP. Gastrointestinal angiodysplasia in heart failure and during CF LVAD support. J Heart Lung Transplant. 2022; 41: 129 – 132.
dc.identifier.citedreferenceJoy PS, Kumar G, Guddati AK, Bhama JK, Cadaret LM. Risk factors and outcomes of gastrointestinal bleeding in left ventricular assist device recipients. Am J Cardiol. 2016; 117: 240 – 244.
dc.identifier.citedreferenceJoly JM, el-Dabh A, Kirklin JK, Marshell R, Smith MG, Acharya D, Rajapreyar IN, Tallaj JA, Tresler M, Pamboukian SV. High right atrial pressure and low pulse pressure predict gastrointestinal bleeding in patients with left ventricular assist device. J Card Fail. 2018; 24: 487 – 493.
dc.identifier.citedreferenceWelden CV, Truss W, McGwin G, Weber F, Peter S. Clinical predictors for repeat hospitalizations in left ventricular assist device (LVAD) patients with gastrointestinal bleeding. Gastroenterology Res. 2018; 11: 100 – 105.
dc.identifier.citedreferenceGonuguntla K, Patil S, Rojulpote C, Cowden RG, Nasir M, Karambelkar P, Buch T, Aujla A, Bhattaru A, Borja ZE, Schulman P. A population based analysis of trends, risk factors and outcomes associated with gastrointestinal bleeding in patients with left ventricular assist devices. Am J Cardiovasc Dis. 2020; 10: 247 – 257.
dc.identifier.citedreferenceKawabori M, Kurihara C, Critsinelis AC, Sugiura T, Kaku Y, Civitello AB, Rosengart TK, Morgan JA. Gastrointestinal bleeding after HeartMate II or HVAD implantation: incidence, location, etiology, and effect on survival. ASAIO J. 2020; 66: 283 – 290.
dc.identifier.citedreferenceJakstaite AM, Luedike P, Schmack B, Pizanis N, Riebisch M, Weymann A, Kamler M, Ruhparwar A, Rassaf T, Papathanasiou M. Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation. ESC Heart Fail. 2021; 8: 2419 – 2427.
dc.identifier.citedreferenceAhsan I, Faraz A, Mehmood A, Ullah W, Ghani AR. Clinical approach to manage gastrointestinal bleeding with a left ventricular assist device (LVAD). Cureus. 2019; 11: e6341.
dc.identifier.citedreferenceBerg D, Lebovics E, Kai M, Spielvogel D. The predicament of gastrointestinal bleeding in patients with a continuous-flow left ventricular assist device: pathophysiology, evaluation, and management. Cardiol Rev. 2019; 27: 222 – 229.
dc.identifier.citedreferenceJoseph Elmunzer B, Padhya KT, Lewis JJ, Rangnekar AS, Saini SD, Eswaran SL, Scheiman JM, Pagani FD, Haft JW, Waljee AK. Endoscopic findings and clinical outcomes in ventricular assist device recipients with gastrointestinal bleeding. Dig Dis Sci. 2011; 56: 3241 – 3246.
dc.identifier.citedreferenceLaine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009; 7: 33 – 47 quiz 1–2.
dc.identifier.citedreferenceGuha A, Eshelbrenner CL, Richards DM, Monsour HP Jr. Gastrointestinal bleeding after continuous-flow left ventricular device implantation: review of pathophysiology and management. Methodist Debakey Cardiovasc J. 2015; 11: 24 – 27.
dc.identifier.citedreferenceNetuka I, Litzler PY, Berchtold-Herz M, Flecher E, Zimpfer D, Damme L, Sundareswaran KS, Farrar DJ, Schmitto JD, EU TRACE Investigators. Outcomes in HeartMate II patients with no antiplatelet therapy: 2-year results from the European TRACE study. Ann Thorac Surg. 2017; 103: 1262 – 1268.
dc.identifier.citedreferenceKatz JN, Adamson RM, John R, Tatooles A, Sundareswaran K, Kallel F, Farrar DJ, Jorde UP, TRACE study. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE study. J Heart Lung Transplant. 2015; 34: 1542 – 1548.
dc.identifier.citedreferenceLim HS, Ranasinghe A, Chue C, Mascaro J. Two-year outcome of warfarin monotherapy in HeartMate 3 left ventricular assist device: a single-center experience. J Heart Lung Transplant. 2020; 39: 1149 – 1151.
dc.identifier.citedreferenceMarshall D, Sanchez J, Yuzefpolskaya M, Sayer GT, Takeda K, Naka Y, Colombo PC, Uriel N, Topkara VK. Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device. J Heart Lung Transplant. 2021; 40: 237 – 240.
dc.identifier.citedreferenceHouston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017; 36: 380 – 385.
dc.identifier.citedreferenceConverse MP, Sobhanian M, Taber DJ, Houston BA, Meadows HB, Uber WE. Effect of angiotensin II inhibitors on gastrointestinal bleeding in patients with left ventricular assist devices. J Am Coll Cardiol. 2019; 73: 1769 – 1778.
dc.identifier.citedreferenceBrinkley DM Jr, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: an IMACS report. J Heart Lung Transplant. 2021; 40: 1605 – 1613.
dc.identifier.citedreferenceJennings DL, Truby LK, Littlefield AJ, Ciolek AM, Marshall D, Jain R, Topkara VK. Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: an INTERMACS analysis. Int J Artif Organs. 2021; 44: 3913988211013366.
dc.identifier.citedreferenceVukelic S, Vlismas PP, Patel SR, Xue X, Shitole SG, Saeed O, Sims DB, Chinnadurai T, Shin JJ, Forest SJ, Goldstein DJ, Jorde UP. Digoxin is associated with a decreased incidence of angiodysplasia-related gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Circ Heart Fail. 2018; 11: e004899.
dc.identifier.citedreferenceKittipibul V, Vutthikraivit W, Kewcharoen J, Rattanawong P, Tantrachoti P, Putthapiban P, Nair N. Angiotensin II antagonists and gastrointestinal bleeding in left ventricular assist devices: a systematic review and meta-analysis. Int J Artif Organs. 2021; 44: 215 – 220.
dc.identifier.citedreferenceMahmoud A, Taha Y, Meece LE, Bavry AA, Ahmed MM. Effect of angiotensin II antagonism on gastrointestinal bleeding in patients with left ventricular assist devices: a systematic review and meta-analysis. ASAIO J. 2022; 68: 1470 – 1474.
dc.identifier.citedreferenceRai D, Tariq R, Tahir MW, Chowdhury M, Wahab A, Kharsa A, Bandyopadhyay D, Feitell SC, Parikh V, Aronow WS, Lanier GM, Levine E, Fonarow GC, Kaul V. Primary and secondary prevention strategies for gastrointestinal bleeding in patients with left ventricular assist device: a systematic review and network meta-analysis. Curr Probl Cardiol. 2021; 46: 100835.
dc.identifier.citedreferenceel Rafei A, Trachtenberg BH, Schultz J, John R, Estep JD, Araujo-Gutierrez R, Suarez TEE, Goodwin K, Cogswell R. Association between digoxin use and gastrointestinal bleeding in contemporary continuous flow left ventricular assist device support. J Heart Lung Transplant. 2021; 40: 671 – 676.
dc.identifier.citedreferenceImamura T, Nguyen A, Rodgers D, Kim G, Raikhelkar J, Sarswat N, Kalantari S, Smith B, Chung B, Narang N, Juricek C, Burkhoff D, Song T, Ota T, Jeevanandam V, Sayer G, Uriel N. Omega-3 therapy is associated with reduced gastrointestinal bleeding in patients with continuous-flow left ventricular assist device. Circ Heart Fail. 2018; 11: e005082.
dc.identifier.citedreferenceHickman AW, Lonardo NW, Mone MC, Presson AP, Zhang C, Barton RG, Selzman CH, Drakos SG, Koliopoulou A, McKellar SH. Acid suppression to prevent gastrointestinal bleeding in patients with ventricular assist devices. J Surg Res. 2019; 234: 96 – 102.
dc.identifier.citedreferenceLiebo M, Newman J, Yu M, Hussain Z, Malik S, Lowes B, Joyce C, Zolty R, Basha HI, Heroux A, McGee E, Um JY, Raichlin E. Preoperative right heart dysfunction and gastrointestinal bleeding in patients with left ventricular assist devices. ASAIO J. 2021; 67: 324 – 331.
dc.identifier.citedreferenceMuthiah K, Connor D, Ly K, Gardiner EE, Andrews RK, Qiao J, Rutgers D, Robson D, Low J, Jarvis S, Macdonald P, Dhital K, Jansz P, Joseph J, Hayward CS. Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2016; 35: 743 – 751.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ehf214433_am.pdf
Size:
473.3KB
Format:
PDF
View/Open
Name:
ehf214433.pdf
Size:
405.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.